A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Trial details
- Registry ID
- NCT06246110
- Phase
- Phase 2
The FDA approved Pemetrexed (Alimta) on 4 Feb 2004.
Drug identity checked against registry records
Also recorded as Alimta; Pemfexy
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110 | Eikon Therapeutics | Phase 2 | Active not recruiting | 2026-12Estimated |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256 | LTRN | Phase 2 | Recruiting | 2026-12Estimated |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 | RCUS | Phase 2 | Completed | 2026-09-17Actual |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 | IOVA | Phase 2 | Terminated | 2026-02-20Actual |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 | RVMD | Phase 1, Phase 2 | Recruiting | 2027-06Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2004-02-04Day | Pemetrexed | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021462", "applicant_as_listed_by_fda": "LILLY", "brand_names": ["ALIMTA"], "active_ingredients": ["PEMETREXED DISODIUM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20040204", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |